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Aims Recent genetic studies identified the rs1333049 variant on chromosome 9p21 as a major susceptibility locus for cor-
onary artery disease and myocardial infarction (MI). Here, we evaluated whether this variant also contributes to
recurrent MI or cardiac death following an acute coronary syndrome (ACS).
Methods
and results
A total of 3247 patients with ACS enrolled in the Global Registry of Acute Coronary Events (GRACE) in three dis-
tinct populations (UK, Belgium and Poland) were prospectively followed for 6 months and genotyped for rs1333049,
in addition to 3004 and 2467 healthy controls from the UK and Belgium. After having confirmed that the at-risk C
allele of rs1333049 was associated with index ACS in the UK and Belgian populations, we found that the rs1333049
at-risk C allele was significantly and independently associated with recurrent MI [age- and gender-adjusted hazard
ratio (HR) 1.48, CI ¼ 1.00–2.19, P ¼ 0.048; and multivariable-adjusted HR 1.47, CI ¼ 0.99–2.18; P ¼ 0.053] and
with recurrent MI or cardiac death (age- and gender-adjusted HR 1.58, CI ¼ 1.00–2.48; P ¼ 0.045; and multivariable
adjusted HR 1.49, CI ¼ 1.03–1.98; P ¼ 0.028) within 6 months after an index ACS. Inclusion of rs1333049 into the
GRACE risk score significantly improved classification for recurrent MI or cardiac death (P ¼ 0.040), as calculated by
the integrated discrimination improvement method.
Conclusion In this large observational study, the 9p21 variant was independently associated with adverse cardiac outcome after
ACS.
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Introduction
Coronary artery disease (CAD) is a complex cardiovascular dis-
order caused by the interaction of environmental factors and her-
editary predisposition.1,2 Recently, the unbiased identification of
genetic variations underlying cardiovascular disease has become a
fruitful enterprise, with at least four genome-wide association
studies identifying chromosome 9p21 as a major locus for risk of
CAD or myocardial infarction (MI).3–6 Strikingly, the pathophysio-
logic effects of the 9p21 locus are not restricted to the coronary
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vasculature, since genetic variants in this locus have also been
linked to abdominal aortic aneurysm, peripheral artery disease,
and stroke.7 In addition, the 9p21 locus has been associated with
prevalence of atherosclerotic plaque in carotid arteries from
healthy individuals, suggesting that the 9p21 locus promotes
atherosclerosis.8
Unresolved questions regarding the role of chromosome 9p21
in CAD still remain. Little is known, for instance, about the
effect of 9p21 in an unbiased population of acute coronary syn-
drome (ACS) patients presenting to hospital. Indeed, most CAD/
MI studies so far were performed in patients with a familial predis-
position (e.g. patients with at least one affected sibling) or in
patients presenting at an early age.3,4,9,10 Furthermore, none of
these studies focused on the full spectrum of ACS, including the
ST-elevation MI (STEMI), non-STEMI, and unstable angina (UA)
subtypes, which differ from each other in the degree of thrombus
formation.11 Importantly, it is also unknown whether the 9p21
locus confers a risk for recurrent MI or cardiac death following
an index ACS. If genetic factors predispose to adverse outcome,
this may influence clinical management. Acute coronary syndrome
patients are most vulnerable to recurrent and lethal cardiovascular
complications during the first 6 months after the primary event,
but identification of those most at risk is elusive, when based on
clinical phenotypes and presentation characteristics. Improved
risk prediction using a combination of phenotypic characteristics
and genetic testing could therefore guide patient triage and
improve acute and longer-term patient care.12
In the present study, we used the Global Registry of Acute Cor-
onary Events (GRACE) program, which is a large, prospective, mul-
tinational observational study of patients hospitalized with ACS.
The GRACE Genetics Study employs standardized criteria for
inclusion and outcome events across the geographically distinct
populations in the UK, Belgium, and Poland. After confirming
that the 9p21 locus associated with primary MI in the GRACE
Genetics Study, we tested whether this association was indepen-
dent from the ACS subtype. We next assessed whether the
9p21 locus correlates with recurrent MI and the combined end-
point consisting of recurrent MI or cardiac death.
Methods
Study populations and phenotype
descriptions
Grace genetics study
The GRACE registry is a large scale, multinational, prospective obser-
vational study of the spectrum of patients with an ACS hospitalized
between July 1999 and December 2007. The GRACE Genetics
Study consists of the 3473 patients from whom DNA was collected
by the eight participating centres in three countries (UK, Belgium,
and Poland) between May 2001 and June 2007. Collected blood
samples were transferred to the core laboratory (The Queens
Medical Research Institute, Edinburgh, UK), where DNA was extracted
and stored at 2808C.
Full details of the methods used in the GRACE registry have been
published previously.13 Briefly, patients were eligible if they were
admitted to participating hospitals with a clinical diagnosis of ACS
and at least one of the following features: electrocardiographic
changes consistent with ACS, increases in serum biochemical
markers of cardiac necrosis [positive troponins, creatinine phosphoki-
nase (CPK), or creatine kinase MB (CK-MB) fraction above two times
the upper limit of normal (ULN)], documented CAD [i.e. history of MI;
congestive heart failure believed to be due to ischaemia or resuscitated
sudden death; history of/or new positive stress test or angina, with or
without imaging; prior or new cardiac catheterization documenting
artery disease, percutaneous coronary intervention (PCI), or coronary
artery bypass graft (CABG)], or both. The presentation of the patients
with ACS was not the consequence of trauma, surgery, or other signifi-
cant co-morbidity (for example anaemia). To ensure enrolment of an
unselected ACS population, sites recruited the first 10–20 consecutive
eligible patients each month. Regular audits were performed at all par-
ticipating hospitals to confirm conformance to eligibility criteria and
correct interpretation of data in the case report form. Trained study
coordinators collected data using standardized case report forms.
Demographic characteristics, medical history, presenting symptoms,
duration of pre-hospital delay, biochemical and electrocardiographic
findings, treatment practices, and outcomes were collected. All cases
were assigned to one of the following categories using predefined cri-
teria: (i) STEMI (including left bundle-branch block), (ii) non-STEMI, (iii)
UA, and (iv) other cardiac or (v) non-cardiac diagnoses.13 All patients
were prospectively followed-up by trained study coordinators at 6
months following admission. Methods of follow-up involved one or
more of the following: phone call to patient, hospital visit, phone call
to patient’s general physician, and/or use of hospital records. All parti-
cipating hospitals were subject to a rigorous on-site 3 years audit cycle,
which involved source verification of randomly selected cases and vali-
dation of outcome events. Outcome events (including recurrent MI)
were prospectively defined using standard definitions for the entire
study, independent of local interpretations.
The primary endpoint for this study was recurrent MI within the first
6 months following the day of hospital admission. A second endpoint
consisted of recurrent MI or cardiac death. Non-cardiac death was
deliberately excluded as an outcome event since there may be multiple
different mechanisms of death without implicating a recurrent myocar-
dial ischaemia or infarction. In-hospital recurrent infarction was con-
firmed by ECG changes or elevation of cardiac markers, as
described previously.12 In patients with acute MI, biomarker criteria
for in-hospital recurrent infarction were: (i) re-elevation of the tropo-
nin above ULN and increase by at least 20% over the previous value or
CK-MB above the ULN and increased by at least 50% over the pre-
vious value. (ii) If CK-MB or troponin were not available, CPK had
to be either .2  ULN and increased by 25% over the previous
value, or .1.5  ULN and increased by at least 50% over the previous
value. (iii) Following PCI or CABG, CK-MB (or CPK) elevation had to
be .3 or .5  ULN, respectively, and increased by at least 50%
over the previous value. (iv) Following CABG, recurrent MI required
biomarker and ECG criteria consistent with MI.13
Local hospital ethics committees approved the GRACE Genetics
Study. All patients provided written informed consent for follow-up
contact and DNA sampling at enrolment, in accordance with the
declaration of Helsinki.
Asklepios study cohort
A total of 2524 participants (1301 women) of 35–55 years, free from
overt cardiovascular disease at study initiation, were randomly sampled
from the twinned Belgian communities of Erpe-Mere and Nieuwerker-
ken, Belgium, between October 2002 and October 2004. Exclusion
criteria were: (i) clinical presence of atherosclerosis or atherothrom-
bosis (symptomatic or haemodynamically significant stenosis, prior
atherothrombotic event, and revascularization); (ii) major concomitant
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illness; (iii) diabetes mellitus type 1 and type 2 if proven macro-
vasculopathy or end-stage renal disease; (iv) conditions precluding
accurate haemodynamic assessment (atrial fibrillation, pregnancy); (v)
inability to provide informed consent.14 Rs1333049 genotypes were
available for 2467 participants (97.7%).
Wellcome Trust Case Control Consortium (WTCCC)
Controls
A total of 3004 controls from the Wellcome Trust Case Control Con-
sortium (WTCCC) (1504 individuals from the 1958 British Birth
Cohort sampled between 2002 and 2004 and 1500 individuals from
the UK Blood Service Group) were used as control population for
the GRACE patients from the UK.3 Genotypic data for rs1333049
were obtained for 2936 participants (97.7%) from the European Gen-
otype Archive (http://www.ebi.ac.uk/ega).
Genotyping of SNPs in the 9p21 locus
The 9p21 locus that is linked with CAD encompasses two linkage dise-
quilibrium (LD) blocks. Based on r2 calculations between SNPs in both
LD blocks, it was demonstrated that rs1333049 is the most representa-
tive SNP for the first block. The association signal in the second block can
bemost consistently captured by three SNPs, i.e. rs7044859, rs1292136,
and rs7865618.4,9We therefore genotyped these four SNPs on the 9p21
locus in a blinded manner using iPLEX technology on a MassARRAY
Compact Analyser (Sequenom Inc., CA,USA), as described previously.15
However, since the first LD block (represented by rs1333049) is most
prominently linked to CAD, we focused most of the analysis on
rs1333049.9 The WTCCC controls were previously genotyped using
the Affymetrix platform (Affymetrix Inc., CA, USA).3
Statistical analysis
Data are summarized as frequencies and percentages for categorical
variables. Continuous variables are presented as medians with 25th
and 75th percentiles. Hardy–Weinberg equilibrium of the genotypes
was assessed using Pearson’s x2-test. For the case–control studies,
the difference in genotype frequencies was calculated using Pearson’s
x2-test. Meta-analysis was performed with the Mantel–Haenszel and
the DerSimonian and Laird method.16 Heterogeneity across the
study populations was calculated using the x2-based Cochran Q stat-
istic.17 Lambda statistics was used to calculate the genetic model of
inheritance, as previously published.18
Formost variables, less than 1%of the datawasmissing. However, for a
number of variables, the percentage of missing values was higher, includ-
ing serum total cholesterol (12.6%), creatinine (3.6%), systolic blood
pressure (2.9%), pulse (3.3%), initial cardiac enzymes (4.0%), Killip class
(2.3%), and the use of thrombolytics (2.3%). Missing values were
sampled using a multiple imputation technique based on the Markov
chain Monte Carlo method (the SAS procedure MI) with seven imputa-
tion data sets. Results were combined using the SAS procedure MIANA-
LYSE. In 38.2% of the patients with a recurrent MI, the time of the
recurrence was missing since it was not collected in initial case report
forms used before July 2002. Missing event times were therefore
imputed by a random draw from observed event times. Incident recur-
rent MI analysis was performed by Cox proportional hazard model
using the SAS procedure PHREG, while considering clinical variables
known to be associated with recurrent MI as covariates.12,19 These
included: age, gender, history of angina, prior MI, diabetes, current
smoking status, systolic blood pressure, heart rate, total cholesterol,
initial serum creatinine level, elevated initial cardiac enzymes, ST
segment depression, Killip class, PCI, CABG, thrombolytics aswell as par-
ticipating country. The cumulative incidence function (CIF) was
calculated and plotted for recurrent MI, assuming competing risk of
death. For recurrentMI or death, theKaplan–Meier curvewas calculated,
using the SAS procedure LIFETEST. Consistency with non-imputed data
was confirmed by repeating the analysis with non-imputed data.
Comparison of the GRACE score for improvement in reclassifica-
tion with and without rs1333049 was done by the Integrated Discrimi-
nation Improvement method, which compares the average difference
in correctly predicting the risk for patients who have a recurrent MI
with those who do not.20
All P-values were two-tailed and ,0.05 was considered statistically
significant. This was a hypothesis-generating and exploratory study, in
which the primary endpoint of interest was the association between
rs1333049 and recurrent MI or cardiac death. Therefore, no adjust-
ments were made to the significance level to account for multiple
testing. Statistical analyses were performed using the SPSS software
version 17.0 (SPSS Inc., IL, USA) and the SAS software version 9.1
(SAS Institute Inc., NC, USA).
Results
Grace genetics study
Overall, 3473 patients were enrolled in the GRACE Genetics
Study. Patients with no diagnosis, a non-cardiac diagnosis, or
with no ACS at the time of hospital discharge (16, 111, and 102
patients, respectively) were excluded. For the remaining 3247
patients with confirmed ACS, follow-up status 24 h after initial
presentation and at a median of 6 months was available for 2980
(91.8%) ACS patients. Of these 2980 patients, genotypes for the
rs1333049 variation were available in 2942 patients (98.7%). The
genotyping success rate for rs1333049 was 98.7%, and 95.2%
for rs7044859, 98.9% for rs496892, and 97.3% for rs7865618.
Fifty-five samples were genotyped twice with an average concor-
dance of 99.8%. No deviation from Hardy–Weinberg equili-
brium was seen in any of the cohorts (P. 0.05).
The median follow-up in these 2942 patients was 195 days [inter-
quartile range (IQR) 185–212] following admission, with a recurrent
MI occurring in 170 patients (5.8%) and a recurrent MI or cardiac
death in 205 patients (7.0%). The median time to recurrence was
12 days (IQR 4–57) for recurrent MI and 29 days (IQR 4–121) for
recurrent MI or cardiac death. In Table 1, demographic character-
istics, medical history, and presenting clinical features are shown
for all patients with a primary ACS. Approximately 28.7% of the
primary ACS patients presented with an ST-segment elevation or a
left bundle branch block, 70.5% had positive cardiac biomarkers of
necrosis, 47.5% had a PCI, and 13.2% received thrombolytics. Con-
sistent with previous studies,21,22 patients with recurrent MI were
older, more likely to have prior history of vascular disease, exhibited
a higherGRACE risk score for an endpoint predicting death or recur-
rent MI, and were more likely to have three-vessel disease, as calcu-
lated by the number of coronary vessels with .50% stenosis
(Table 1). In addition, patients with a non-STEMI and those treated
with thrombolytics were more prone to recurrent MI.
9p21 increases the risk for acute coronary
syndrome in a hospital-based population
In order to validate the association of rs1333049 with CAD in the
GRACE Genetics Study, we first assessed whether the rs1333049
I. Buysschaert et al.1134
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Table 1 Baseline clinical variables predicting a recurrent myocardial infarction in the GRACE Genetics Study
Variables Total No recurrent MI Recurrent MI OR (95% CI) P-value
No. of patients (%) 2942 2772 (94.2%) 170 (5.8%)
Demographics
Men, n (%) 1984 (67.9%) 1869 (67.9%) 115 (68.9%) 1.05 (0.75–1.46) 0.79
Age, median (25th–75th percentiles), year 65 (55–73) 65 (55–73) 70 (61–79) 1.04 (1.03–1.06) ,0.001
BMI, median (25th–75th percentiles), kg/m2 27.04 (24.37–30.10) 27.04 (24.38–30.10) 27.04 (24.22–29.91) 1.00 (0.99–1.00) 0.85
Medical History, n (%)
Angina 1628 (55.5%) 1515 (54.8%) 113 (66.5%) 1.64 (1.18–2.27) 0.003
Diabetes 500 (17.0%) 458 (16.6%) 42 (24.7%) 1.65 (1.15–2.38) 0.007
Prior MI 799 (27.3%) 729 (26.4%) 70 (41.2%) 1.95 (1.42–2.68) ,0.001
Congestive heart failure 200 (6.8%) 179 (6.5%) 21 (12.4%) 2.05 (1.26–3.31) 0.004
Stroke or transient ischaemic attack 173 (5.9%) 164 (5.8%) 12 (7.1%) 1.23 (0.67–2.26) 0.51
Prior PCI 408 (13.9%) 381 (13.8%) 27 (15.9%) 1.18 (0.77–1.81) 0.44
Prior CABG 240 (8.2%) 223 (8.1%) 17 (10%) 1.27 (0.75–2.13) 0.37
Peripheral arterial disease 217 (7.4%) 190 (6.9%) 27 (16.0%) 2.57 (1.66–3.98) ,0.001
Hypertension 1587 (54.2%) 1491 (54.0%) 96 (56.5%) 1.10 (0.81–1.51) 0.53
Hyperlipidaemia 1192 (40.7%) 1121 (40.6%) 71 (41.8%) 1.05 (0.76–1.43) 0.77
Combined history of atherosclerosis 1853 (63.2%) 1722 (62.3%) 131 (77.1%) 2.03 (1.41–2.93) ,0.001
Family history of coronary artery disease 581 (26.1%) 559 (26.3%) 22 (22.4%) 0.81 (0.50–1.31) 0.39
Smoking status, n (%)
Current 874 (30.3%) 831 (30.6%) 43 (25.4%) 0.77 (0.54–1.10) 0.16
Former 786 (27.2%) 739 (27.2%) 47 (27.8%) 1.03 (0.73–1.46) 0.86
Presenting characteristics
Positive initial enzymes, n (%) 1991 (70.5%) 1860 (69.9%) 131 (79.1%) 1.71 (1.15–2.52) 0.007
ST elevation or LBBB, n (%) 843 (28.7%) 793 (28.6%) 50 (29.4%) 1.04 (0.74–1.46) 0.82
ST depression or T wave inversion, n (%) 1032 (35.1%) 949 (34.2%) 83 (48.8%) 1.83 (1.34–2.50) ,0.001
Systolic blood pressure, median (25th–75th
percentiles), mmHg
140 (120–160) 140 (120–159) 140 (120–160) 1.00 (0.99–1.01) 0.21
Diastolic blood pressure, median (25th–75th
percentiles), mmHg
80 (70–90) 80 (70–90) 80 (70–90) 1.00 (0.99–1.01) 0.66
Pulse (25th–75th percentiles), b.p.m. 75 (64–87) 75 (64–86) 80 (65–96) 1.01 (1.00–1.02) 0.005
Killip class, n (%) ,0.001
I 2271 (79.0%) 2163 (79.9%) 108 (65.1%) Reference
II 524 (18.2%) 476 (17.6%) 48 (28.9%) 2.02 (1.42–2.88) ,0.001
III 68 (2.4%) 58 (2.1%) 10 (6.0%) 3.45 (1.72–6.94) 0.001
IV 11 (0.4%) 11 (0.4%) 0 (0%) N/A N/A
Creatinine, median (25th–75th percentiles), mg/
dL
1.04 (0.90–1.22) 1.04 (0.90–1.22) 1.13 (0.96–1.39) 1.22 (1.03–1.45) 0.02
Serum cholesterol, median (25th–75th
percentiles), mg/dL
194 (166–228) 194 (166–229) 184 (159–213) 0.99 (0.99–1.00) 0.03
GRACE risk score
Probability of in-hospital death or MI, median
(25th–75th percentiles), %
11 (8–17) 11 (8–17) 14 (9–19) 1.04 (1.02–1.06) ,0.001
Probability of death or MI 6 months after
discharge, median (25th–75th percentiles), %
4 (3–8) 4 (3–8) 7.5 (4–15) 1.05 (1.03–1.07) ,0.001
Diagnosis 0.01
STEMI, n (%) 768 (27.2%) 724 (27.2%) 44 (26.8%) 0.99 (0.69–1.41)
Non-STEMI, n (%) 1223 (43.3%) 1136 (42.7%) 87 (53.0%) 1.51 (1.11–2.06)
UA, n (%) 833 (29.5%) 800 (30.1%) 33 (20.1%) 0.59 (0.40–0.88)
Continued
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variation was associated with ACS and therefore performed a
case–control association study for the UK and Belgian
GRACE patients. To this extent, we used population-based DNA
cohorts from the two countries: 2936 participants from the
WTCCC study3 and 2467 individuals from the Asklepios
Study.14 GRACE patients from Poland were not used because no
population-based control cohort with existing genotypic infor-
mation for rs1333049 was available. In the UK and Belgian sub-
studies, the at-risk C allele of rs1333049 was uniformly associated
with ACS with respective odds ratios of 1.25 (CI ¼ 1.13–1.39;
P ¼ 1.0  1025) and 1.15 (CI ¼ 1.02–1.29; P ¼ 0.024), and a
pooled OR of 1.21 (CI ¼ 1.10–1.32; P ¼ 2.4  1026 under a
fixed effects model, P ¼ 4.6  1025 under a random effects
model; P for heterogeneity ¼ 0.189) for both studies. Genotypic
analysis showed that the pooled risk of carrying a single C allele
was 1.20 and the risk of carrying two at-risk C alleles was 1.45
(see Supplementary material online, Table S1). Overall, the
observed risk effects were in accordance with those observed in
previous studies3,4,9 demonstrating that the rs1333049 variant is
also a risk factor for unselected patients with ACS seen in daily
practice.
Association of 9p21 with clinical subtypes
of acute coronary syndrome
Having confirmed that rs1333049 is a risk factor for ACS also in
the GRACE Genetics Study, we next assessed whether the
rs1333049 acts independently from known clinical risk factors
for cardiovascular disease to increase susceptibility for ACS. As
shown in Table 2, no significant differences for any of the demo-
graphic or phenotypic risk factors were seen. Remarkably,
rs1333049 genotypes were also similarly distributed among the
different ACS subtypes (STEMI, non-STEMI, and UA), thus indicat-
ing that the full spectrum of ACS, rather than a particular subtype,
was associated with rs1333049 (Table 2).
Although previous studies reported an association between
rs1333049 and prevalent atherosclerosis in carotid vessels from
healthy individuals,23 we only observed a weak trend towards
association of rs1333049 and prior history of atherosclerosis,
with carriers of two at-risk C alleles being slightly more
common (26.8 vs. 24.9%; P ¼ 0.19, Table 2). In addition, there
was also no significant association between rs1333049 and three-
vessel disease (P ¼ 0.64).
Association of 9p21 with recurrent
myocardial infarction or cardiac death
We then assessed whether 9p21 was also associated with recur-
rent atherothrombotic events. Survival analysis in the GRACE
Genetics Study (n ¼ 2942) revealed that rs1333049 was signifi-
cantly associated with recurrent MI (n ¼ 170) within the first
6 months after the primary event. This risk effect followed a domi-
nant genetic model (see Supplementary material online, Table S2),
in which the presence of any at-risk C allele predicted recurrent MI
with an age- and gender-adjusted hazard ratio (HR) of 1.48 (CI ¼
1.00–2.19, P ¼ 0.048) and a similar effect after multivariable
adjustment (HR 1.47; CI ¼ 0.99–2.18; P ¼ 0.053; Table 3). The
CIF illustrating that a recurrent MI is more common in C allele car-
riers vs. non-carriers is shown in Figure 1. Consistency with non-
imputed data was confirmed by repeating the analysis without
imputation and revealed comparable results (multivariable adjusted
HR 2.30, CI ¼ 1.27–4.09, P ¼ 0.006). To further dissect this
association with recurrent MI, genotype distributions of three
additional SNPs in the 9p21 locus (rs7044859, rs1292136, and
rs7865618), as well as their haplotype distributions, were
studied. However, no additional relevant associations were
detected (Supplementary material online, Tables S3 and S4).
Since cardiac death is often precipitated by ischaemic heart
disease, we used a second combined endpoint consisting of recur-
rent MI or cardiac death. In agreement with the primary endpoint
analysis, rs1333049 was significantly associated with recurrent MI
or cardiac death (n ¼ 205) within the first 6 months after the
primary event (P ¼ 0.045 and P ¼ 0.028, respectively, after age-
and gender-adjustment and multivariable adjustment; Table 4 and
Figure 2). Consistency with non-imputed data was confirmed by
repeating the analysis without imputation (multivariable adjusted
HR 2.28, CI ¼ 1.27–4.09, P ¼ 0.0057).
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Table 1 Continued
Variables Total No recurrent MI Recurrent MI OR (95% CI) P-value
Treatment
Cardiac catheterization, n (%) 1926 (65.8%) 1817 (65.9%) 109 (64.5%) 0.94 (0.60–1.30) 0.71
Three-vessel disease (.50% stenosis), n (%) 445 (23.1%) 400 (22.0%) 45 (41.3%) 2.35 (1.58–3.51) 0.001
Left main (.50% stenosis), n (%) 138 (7.2%) 127 (7.0%) 11 (10.1%) 0.70 (0.35–1.28) 0.22
PCI, n (%) 1397 (47.5%) 1325 (47.9%) 72 (42.4%) 0.80 (0.58–1.09) 0.16
Thrombolytics, n (%) 380 (13.2%) 342 (12.6%) 38 (22.8%) 2.04 (1.39–2.98) ,0.001
CABG, n (%) 111 (3.8%) 103 (3.7%) 8 (4.7%) 1.28 (0.61–2.67) 0.51
Data were analysed by logistic regression. Combined history of atherosclerosis comprehends medical history of angina, prior MI, stroke or transient ischaemic attack, prior PCI,
CABG, or peripheral arterial disease. A 50% stenosis cut-off was used to determine presence or absence of CAD, instead of a 70% stenosis cut-off, which is used to denominate
clinically significant stenosis.
CABG, coronary artery bypass graft; CI, confidence interval; LBBB, left bundle branch block; MI, myocardial infarction; N/A, non-applicable; OR, odds ratio; PCI, percutaneous
coronary intervention; STEMI, ST-segment elevated myocardial infarction; UA, unstable angina.
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Table 2 Baseline clinical variables according to rs1333049 genotype in the GRACE Genetics Study
Variables Total rs1333049 Genotype P-value
GG GC CC
No. of patients (%) 2942 726 (24.7%) 1460 (49.6%) 756 (25.7%)
Demographics
Men, n (%) 1984 (67.9%) 485 (67.4%) 992 (68.4%) 507 (67.6%) 0.86
Age, median (25th–75th percentiles), year 65 (55–73) 65 (56–73) 65 (55–73) 66 (56–74) 0.18
BMI, median (25th–75th percentiles), kg/m2 27.0 (24.4–30.1) 26.8 (24.2–30.1) 27.1 (24.5–30.1) 27.1 (24.3–30.1) 0.60
Medical history, n (%)
Angina 1628 (55.5%) 390 (53.9%) 797 (54.7%) 441 (58.5%) 0.15
Diabetes 500 (17.0%) 122 (16.8%) 248 (17.0%) 130 (17.3%) 0.97
Prior MI 799 (27.3%) 195 (26.2%) 381 (26.2%) 223 (29.5%) 0.25
Congestive heart failure 200 (6.8%) 53 (7.3%) 101 (7.0%) 46 (6.1%) 0.62
Stroke or transient ischaemic attack 173 (5.9%) 43 (5.9%) 82 (5.6%) 48 (6.4%) 0.78
Prior PCI 408 (13.9%) 99 (13.7%) 204 (14.0%) 105 (13.9%) 0.98
Prior CABG 240 (8.2%) 46 (6.4%) 130 (8.9%) 64 (8.5%) 0.11
Peripheral arterial disease 217 (7.4%) 48 (6.6%) 113 (7.8%) 56 (7.5%) 0.63
Hypertension 1587 (54.2%) 404 (55.9%) 764 (52.6%) 419 (55.6%) 0.23
Hyperlipidaemia 1192 (40.7%) 308 (42.7%) 573 (38.4%) 311 (41.4%) 0.30
Combined history of atherosclerosis 1853 (63.2%) 449 (62.1%) 907 (62.3%) 497 (65.9%) 0.19
Family history of coronary artery disease 581 (26.1%) 144 (26.1%) 282 (25.4%) 155 (27.6%) 0.62
Smoking status, n (%)
Current 874 (30.3%) 214 (30.2%) 445 (31.1%) 215 (29.0%) 0.62
Former 785 (27.2%) 180 (25.4%) 395 (27.6%) 210 (28.3%) 0.43
Presenting characteristics
Positive initial enzymes, n (%) 1991 (70.5%) 484 (69.4%) 991 (70.2%) 516 (72.1%) 0.53
ST elevation or LBBB, n (%) 843 (28.7%) 201 (27.7%) 430 (29.5%) 212 (28.7%) 0.63
ST depression or T wave inversion, n (%) 1032 (35.1%) 252 (34.7%) 506 (34.7%) 274 (36.2%) 0.74
Systolic blood pressure, median (25th–75th percentiles),
mmHg
140 (120–160) 140 (120–160) 138 (120–156) 140 (120–160) 0.072
Diastolic blood pressure, median (25th–75th percentiles),
mmHg
80 (70–90) 80 (70–90) 80 (70–90) 80 (70–90) 0.33
Pulse (25th–75th percentiles), b.p.m. 75 (64–87) 75 (64–88) 75 (64–86) 75 (65–90) 0.59
Killip class, n (%) 0.86
I 2271 (79.0%) 558 (79.3%) 1118 (78.6%) 595 (79.5%)
II 524 (18.2%) 127 (18.0%) 267 (18.8%) 130 (17.4%)
III 68 (2.4%) 18 (2.6%) 31 (2.2%) 19 (2.5%)
IV 11 (0.4%) 1 (0.1%) 6 (0.4%) 4 (0.4%)
Creatinine, median (25th–75th percentiles), mg/dL 1.04 (0.90–1.22) 1.06 (0.90–1.23) 1.04 (0.90–1.21) 1.03 (0.90–1.23) 0.57
Serum cholesterol, median (25th–75th percentiles), mg/dL 194 (166–228) 194 (164–228) 195 (166–228) 193 (166–229) 0.99
GRACE risk score
Probability of in-hospital death or MI, median (25th–75th
percentiles), %
11 (8–17) 11 (8–16) 11 (7–17) 11 (8–17) 0.63
Probability of death or MI 6 months after discharge, median
(25th–75th percentiles), %
4 (3–8) 4 (3–8) 4 (3–8) 5 (3–8) 0.28
Diagnosis 0.53
STEMI, n (%) 768 (26.1%) 178 (24.5%) 397 (27.2%) 193 (25.5%)
Non-STEMI, n (%) 1223 (41.6%) 306 (42.1%) 594 (40.7%) 323 (42.7%)
UA, n (%) 833 (28.3%) 213 (29.3%) 420 (28.8%) 200 (26.5%)
Continued
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We also assessed whether the 9p21 genetic risk locus improved
the prediction of a recurrent MI or cardiac death by quantifying the
improvement in risk classification after adding rs1333049 into the
GRACE risk score for recurrent MI.12 To this extend, the inte-
grated discrimination improvement (IDI) index was used.20
Inclusion of rs1333049 into the prediction model showed a
trend towards improved classification of recurrent MI at 6
months; this effect failed, however, to reach significance (P ¼
0.073). However, risk classification for the combined endpoint
consisting of recurrent MI or cardiac death was significantly
improved (P ¼ 0.040): an additional 5.93% of the patients had an
increased probability of being correctly classified after inclusion
of rs1333049 into the model.
Discussion
The GRACE Genetics Study was used to better characterize the
9p21 genetic risk locus for CAD. Our findings are relevant in
several respects.
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Table 2 Continued
Variables Total rs1333049 Genotype P-value
GG GC CC
Treatment
Cardiac catheterization, n (%) 1926 (65.8%) 469 (64.7%) 980 (67.4%) 577 (63.7%) 0.16
Three-vessel disease (.50% stenosis), n (%) 445 (27.4%) 108 (23.9%) 231 (25.6%) 106 (23.5%) 0.64
Left main (.50% stenosis), n (%) 138 (7.2%) 24 (5.1%) 76 (7.8%) 38 (8.0%) 0.14
PCI, n (%) 1397 (47.5%) 343 (47.2%) 709 (48.6%) 345 (45.8%) 0.44
Thrombolytics, n (%) 380 (13.2%) 94 (13.2%) 193 (13.5%) 93 (12.6%) 0.83
CABG, n (%) 111 (3.8%) 23 (3.2%) 62 (4.3%) 26 (3.5%) 0.39
Data were analysed by Kruskal–Wallis or x2 test. Abbreviations are the same as in Table 1.
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Table 3 Association of rs1333049 with recurrent myocardial infarction in the GRACE Genetics Study
rs1333049 No recurrent MI Recurrent MI Age- and gender-adjusted Multivariable-adjusteda
2772 (94.2%) 170 (5.8%) HR (95% CI) P-Value HR (95% CI) P-Value
Genotypic, n (%)
CC 710 (25.6%) 46 (27.1%) 1.41 (0.89–2.23) 0.14 1.34 (0.84–2.12) 0.21
GC 1367 (49.3%) 93 (54.7%) 1.52 (1.01–2.28) 0.044 1.55 (1.03–2.33) 0.037
GG 695 (25.1%) 31 (18.2%) Reference Reference
Dominant, n (%)
CC þ GC 2077 (74.9%) 139 (81.8%) 1.48 (1.00–2.19) 0.048 1.47 (0.99–2.18) 0.053
GG 695 (25.1%) 31 (18.2%) Reference Reference
Data are analysed by a Cox proportional hazard model.
CI, confidence interval; HR, hazard ratio.
aAdjustments for: age, gender, history of angina, prior myocardial infarction, diabetes, current smoking status, systolic blood pressure, heart rate, total cholesterol, initial serum
creatinine level, elevated initial cardiac enzymes, ST segment depression, Killip class, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG),
thrombolytics, and participating country.
Figure 1 Cumulative incidence function for recurrent myocar-
dial infarction (MI) by rs1333049 genotype in the GRACE Gen-
etics Study. The cumulative incidence function for recurrent MI
by rs1333049 genotype is shown, comparing individuals carrying
1 or 2 at-risk C alleles (GC and CC) vs. individuals carrying no
risk alleles (GG).
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The most important finding is that the 9p21 locus predisposes to
recurrent MI or cardiac death. Indeed, in ACS patients receiving
optimal secondary prevention treatments, we found that carriers
of the at-risk C allele exhibited an increased risk to develop a
recurrent MI or cardiac death within 6 months after the primary
event. Interestingly, the HR for developing a recurrent event in
these carriers was higher than the risk of having a primary event
(HR ¼ 1.49 for recurrent MI or cardiac death vs. OR ¼ 1.26 for
primary ACS). This is remarkable, since patient populations with
a primary ACS are already enriched for the rs1333049 at-risk C
allele. In agreement herewith, the percentage of individuals carrying
a C allele in the various patient groups increased gradually with the
number of coronary events, i.e. 72.5% in healthy individuals com-
pared with 74.9% in all primary ACS patients and as much as
81.8% in patients with a recurrent MI or cardiac death. The signifi-
cant association of rs1333049 with recurrent MI or cardiac death
could also generate intriguing insights into the biological role of
9p21 in CAD. Indeed, previous genetic studies investigating the
9p21 locus have used heterogeneous patient groups, consisting
of stable CAD, coronary revascularization, or MI patients. Conse-
quently, it has been impossible to conclude whether 9p21 drives
atherosclerotic plaque formation, promotes plaque rupture, or
triggers both. A study by Ye et al.,23 which demonstrates that
9p21 is associated with prevalence and 5 years progression of pre-
clinical atherosclerosis in carotid vessels, suggests that 9p21 pro-
motes plaque formation. It is therefore possible that GRACE
patients carrying the rs1333049 allele develop more extensive
atherosclerosis, and are more prone to a recurrent infarction.
However, since we limited the follow-up period between the
primary and recurrent event to 6 months, it is also possible 2if
not more likely2 that recurrent events were due to subsequent
rupture of pre-existing plaques. In this regard, our data also
suggest a role for 9p21 in plaque rupture. Nevertheless, as long
as the functional effect of rs1333049 on neighbouring genes is
not known, it might be difficult to draw definite conclusions
about the mechanisms by which rs1333049 exerts its effect on
recurrent MI.
Our data may seem surprising since Horne et al.24 could not
establish an association between the 9p21 locus and a combined
endpoint of non-fatal MI and death, suggesting that 9p21 was not
associated with MI. However, the differences in patient selection
and outcome criteria between Horne’s study and GRACE might
explain why we did observe such association in the present
study. Indeed, Horne et al. retrospectively selected patients from
an angiographic database, which included stable and UA, and MI
patients, while GRACE prospectively selected consecutive ACS
patients only. As endpoint, Horne et al. used primary MI, recurrent
MI, as well as all-cause moralities, whereas GRACE only con-
sidered recurrent MI and/or cardiac death.
Remarkably, the association of rs1333049 with recurrent MI or
cardiac death was independent of all other risk factors, suggesting
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Table 4 Association of rs1333049 with recurrent myocardial infarction or cardiac death in the GRACE Genetics Study
rs1333049 No recurrent MI
or cardiac death
Recurrent MI
or cardiac death
Age- and gender-adjusted Multivariable-adjusteda
2737 (93.0%) 205 (7.0%) HR (95% CI) P-value HR (95% CI) P-value
Genotypic, n (%)
CC 701 (25.6%) 55 (26.8%) 1.39 (0.82–2.37) 0.22 1.33 (0.88–2.03) 0.18
GC 1347 (49.2%) 113 (55.1%) 1.69 (1.06–2.69) 0.028 1.58 (1.09–2.30) 0.016
GG 689 (25.2%) 37 (18.0%) Reference Reference
Dominant, n (%)
CC þ GC 2048 (74.8%) 168 (82.0%) 1.58 (1.00–2.48) 0.045 1.49 (1.03–1.98) 0.028
GG 689 (25.2%) 37 (18.0%) Reference Reference
Data are analysed by a Cox proportional hazard model.
CI, confidence interval; HR, hazard ratio.
aAdjustments as in Table 4.
Figure 2 Cumulative incidence of recurrent MI or cardiac
death by rs1333049 genotype in the GRACE Genetics Study. A
Kaplan–Meier curve analysis for recurrent MI or cardiac death
by rs1333049 genotype is shown, comparing individuals carrying
1 or 2 at-risk C alleles (GC and CC) vs. individuals carrying no
risk alleles (GG).
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that rs1333049 may be used as an additional variable in clinical risk
prediction models for recurrent MI. We tested this hypothesis
using the GRACE risk score, which has been developed and vali-
dated for the robust prediction of cumulative 6 months risk of
death or MI.12 We found that inclusion of rs1333049 into the
GRACE risk score did not significantly improve risk classification
for the prediction of recurrent MI (P ¼ 0.073), but significantly
improved risk classification of the combined endpoint of recurrent
MI or cardiac death (P ¼ 0.040) at 6 months using the integrated
discrimination improvement method. It can therefore be antici-
pated that inclusion of additional genetic factors, which are likely
to be identified in the near future, in combination with
rs1333049 could enhance risk prediction models for adverse
outcome following ACS.
Another finding of the study is that rs1333049 is a risk factor for
primary ACS in two geographically different populations from the
UK and Belgium. Although the primary reason for performing this
analysis was to validate the GRACE Genetics Study, the findings
from our case–control association study are of additional interest.
Indeed, since the large majority of patients studied previously were
a mixture of CAD or MI patients, which were either genetically
enriched or exhibited early disease onset,3,4,9,10 risk effects in the
latter cohorts may have been overestimated. However, in our pro-
spective and consecutively collected GRACE Genetics Study, the
risk associated with rs1333049 was largely comparable to that of
previous reports: the odds ratio per C allele in the GRACE Gen-
etics Study was 1.21 compared with 1.24 in the meta-analysis from
Schunkert et al.9 Our study thus confirms that the risk associated
with rs1333049 is applicable to patient populations as seen in clini-
cal practice.
The strength of the GRACE Genetics Study is its specific design
to capture an unselected and representative population of ACS
patients with carefully characterized baseline and prospective
follow-up data. In particular, standardized inclusion criteria and
definitions of outcome events, which were independent of local
interpretations in each of the participating clinical centres, were
used. Another strength of the study is the inclusion of three geo-
graphically distinct populations, with variations in environmental
risk factors and different incidence and prevalence rates for
CAD. This suggests that the findings were not specific to a particu-
lar population or to a specific collection of risk factors in one
country. It should be noted, however, that this study has also a
number of limitations. First, we have used in the case–control
study for primary ACS control populations that were not age-
or gender-matched to the GRACE patients. However, since
these control populations consisted of younger participants,
which are yet to develop cardiovascular events, relatively more
at-risk C allele carriers would be expected in these control popu-
lations compared with older cohorts, suggesting that our observed
odds ratios would be an under-estimation, rather than over-
estimation of the true risk effect. Second, since we do not have
genome-wide SNP data for GRACE, we could not assess popu-
lation substructure by multidimensional scaling or principal com-
ponent analysis.25 A third limitation is the small effective sample
size of the recurrent MI or cardiac death population. Indeed,
only 5.8 (n ¼ 170) and 7.0% (n ¼ 205) of all primary ACS patients
developed a recurrent MI or recurrent MI/cardiac death event.
Additional replication studies are therefore needed to confirm
our findings. Finally, periprocedural MI was not part of the initial
case record form in GRACE, thereby precluding a sub-analysis
excluding periprocedural MI from the endpoints. Because we
only included a recurrent MI occurring at 24 h or later after the
primary event and because periprocedural MI occurs in the
majority of the patients within the first 24 h, we expect that
most periprocedural MIs will automatically have been excluded
by this definition.
In conclusion, our study confirms that the 9p21 locus confers a
risk for primary ACS in an unselected patient population. Impor-
tantly, we also provide unprecedented evidence that the 9p21
locus is independently associated with recurrent MI or cardiac
death following an acute coronary event. Since the follow-up
period between the primary and recurrent event was restricted
to 6 months, our data suggest that the 9p21 locus—in addition
to promoting plaque formation—might also be involved in stimu-
lating plaque instability and rupture. Finally, we provide suggestive
evidence that prediction models for recurrent events might be
complemented by genetic risk factors such as the 9p21 locus.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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